- Prof. Dr. Thomas Kraus
- Project duration:
- 01.01.2019 to 31.12.2021
- EU contribution:
- 2.686.677 euros
Airway Disease Analysis and Prevention
ADAPT will validate an entirely new, non-invasive diagnostic device for topical sampling of chronic airway diseases and combine it with an innovative panel of precision-medicine biomarkers. The solution will allow early detection and differentiation of allergic rhinitis and asthma endotypes, which are responsive to prevention and specific treatment. The innovation opens new avenues in precision medicine, allergy prevention and home care.
The ADAPT solution combines the newly developed biomarker candidate panel with “Nasosorption™ FX·i”, a safe, single-use device for non-invasive nasal sampling. The added value of this concept is that the more sensitive assessment is applicable in clinical practice, even in children or the elderly. The diagnostic test is envisioned as a tool for primary care, and there has also been consideration of developing it further, for home-care settings.
EIT Health supports the validation of this unique innovation and facilitates the bridging of accumulated knowledge in research and commercialisation from world leaders in the immunodiagnostic industry.
- Technische Universität München, Germany (Coordinator)
- Imperial College London, United Kingdom
- Medical University of Łódź, Poland
- Thermo Fisher Scientific - Phadia AG, Sweden
This activity has received funding from the European Institute of Innovation and Technology (EIT), a body of the European Union, under the Horizon 2020, the EU Framework Programme for Research and Innovation.